𝐓𝐡𝐞 𝐈𝐧𝐝𝐢𝐚𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐩𝐨𝐞𝐢𝐚 𝐰𝐡𝐢𝐜𝐡 𝐢𝐬 𝐥𝐢𝐤𝐞𝐥𝐲 𝐭𝐨 𝐛𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐟𝐫𝐨𝐦 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 1, 2022.
It will impact public health in the long term in a big way. Of the 92 new monographs, there are 60 chemicals, 21 vitamins, minerals, amino acids, fatty acids, etc., 3 biotechnology-derived therapeutic products, 4 human vaccines, 2 blood and blood related products, 2 herbs and herbal related products, and 7 phytopharmaceutical ingredient category monographs.
Besides this, IP 2022 also contains 652 pharma reference substances covering 70 per cent requirement of reference materials used for quality control in the country. Currently, there are 300 impurity standards in IP which are crucial for managing pharmaceutical quality. So, there are a total number of 3152 monographs in the current edition of IP. Several monographs and general chapters have also been revised to update them as per current global requirements and to harmonize with other pharmacopoeias like USP, BP, EP, etc.
The harmonization of standards with global standards is expected to help IP getting recognized and accepted in foreign countries.
The ministry deserves kudos for releasing the latest version of the pharmacopoeia as it is important to maintain standard quality of medical products - vaccines, medicines, equipment, etc. and to keep an eye on the effect of these medicines on patients.
Definitely, the 9th edition of IP will be a step forward to deliver quality medicines to the public at large.